• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amicus Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    5/1/25 6:00:38 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOLD alert in real time by email
    false 0001178879 0001178879 2025-04-28 2025-04-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT PURSUANT TO

    SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): April 28, 2025

     

    AMICUS THERAPEUTICS, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware   001-33497   71-0869350
    (State or Other Jurisdiction
    of Incorporation)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification No.)

     

    47 Hulfish Street, Princeton, New Jersey 08542

    (Address of Principal Executive Offices, and Zip Code)

     

    609-662-2000

    Registrant’s Telephone Number, Including Area Code

     

    (Former Name or Former Address, if Changed Since Last Report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock Par Value $0.01   FOLD   NASDAQ

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company  ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     
     

     

    Item 1.01 – Entry into a Material Definitive Agreement.

     

    Dimerix License Agreement

     

    On April 30, 2025, Amicus Therapeutics, Inc. (“Amicus”) entered into a License Agreement, effective May 1, 2025 (the “Agreement”) with Dimerix Bioscience Pty Ltd. (“Dimerix”), pursuant to which, among other things, Dimerix granted Amicus the exclusive rights to develop, manufacture, and commercialize Dimerix’s small molecule inhibitor of the chemokine receptor 2 (CCR2) drug candidate known as DMX-200, and other related compounds, and products containing DMX-200 and other licensed compounds, in the United States for Focal Segmental Glomerulosclerosis (“FSGS”) and other indications.

     

    Under the Agreement, Dimerix will continue to fund and execute the current and ongoing pivotal Phase 3 study for DMX-200 for FSGS. Dimerix and Amicus will collaborate with respect to regulatory matters relating to licensed products in the United States pursuant to the Agreement, with Amicus being responsible for submitting New Drug Applications (“NDAs”) for licensed products (including the NDA for DMX-200 for FSGS) in the United States and thereafter controlling, in collaboration with Dimerix, all regulatory matters in the United States for licensed products. Amicus is obligated to use commercially reasonable efforts to develop licensed products for indications beyond FSGS and to initiate clinical development in at least one indication other than FSGS, within an agreed time period after receipt of full regulatory approval of DMX-200 for FSGS in the United States, in order to retain rights to licensed products for all indications. Amicus is also obligated to use commercially reasonable efforts to commercialize licensed products in the United States following receipt regulatory approval and in a manner that is materially consistent with Amicus’s commercialization plan for the licensed products.

     

    Dimerix will manufacture and supply DMX-200 and licensed products for Amicus using its existing third-party contract manufacturing organization under a supply agreement to be negotiated between Dimerix and Amicus following the effective date of the Agreement.

     

    Amicus will grant Dimerix an exclusive license (with the right to sublicense) under certain know-how and patent rights generated through activities conducted by Amicus, its affiliates or sublicensees under the Agreement for Dimerix to use in the development, manufacture, or commercialization of DMX-200 and other licensed products outside of the United States.

     

    Upon the effective date of the Agreement, Amicus will pay to Dimerix an upfront fee of $30 million US dollars. Amicus will also be obligated to pay Dimerix for certain (i) success-based development and regulatory milestones for FSGS of up to a maximum aggregate amount of $75 million US dollars, (ii) regulatory milestones for other indications of up to a maximum aggregate amount of $40 million US dollars and (iii) commercial milestones of up to a maximum aggregate amount of $445 million US dollars.

     

    Amicus is also obligated to pay Dimerix royalties ranging from percentages in the low-teens to low-twenties on net sales of licensed products, subject to certain customary reductions and offsets. These royalties are payable, on a licensed product-by-licensed product basis, until the latest of (i) the expiration of certain patent rights covering the relevant licensed product in the United States, (ii) the expiration of all regulatory exclusivity for such licensed product in the United States, or (iii) an agreed period of time after the first commercial sale of such licensed product in the United States.

     

    From the effective date of the Agreement until a specific period of time after receipt of the first regulatory approval for a licensed product in the United States, neither Amicus nor Dimerix may, directly or indirectly, conduct any clinical development or commercial activities in the United States involving (a) any product for the treatment of FSGS nor (b) any product that antagonizes CCR2 as its primary mechanism of action, other than with respect to a licensed product under the Agreement, and subject to certain exclusions for independent programs of an acquirer of either party that remain segregated following a change of control of the relevant party.

     

    Unless earlier terminated, the Agreement will continue on a licensed product-by-licensed product basis, until there are no more royalty payments owed to Dimerix with respect to such licensed product and Amicus will have a non-exclusive, fully paid-up license after the expiration of the royalty term for a licensed product. Each party may terminate the Agreement in its entirety if the other party remains in material breach of the Agreement following a cure period to remedy the material breach. Amicus may terminate the Agreement in its entirety for convenience and after giving a specified amount of prior notice to Dimerix, but Amicus may not do so for a certain period of time after the effective date of the Agreement, unless the termination is based on the occurrence of a material adverse safety event with respect to a licensed product. Dimerix may additionally terminate the Agreement, subject to a specified cure period, if Amicus challenges any patents licensed to Amicus under the Agreement.

     

    The foregoing description of the Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of such Agreement. Amicus intends to redact certain portions of the Agreement in accordance with applicable law and expects to file a copy of the Agreement as an exhibit to Amicus’ Quarterly Report on Form 10-Q for the quarter ending June 30, 2025.

     

     

     

     

    Blackstone Agreement

     

    On April 28, 2025, Amicus entered into an amendment (the “First Amendment”) to the Loan Agreement, dated October 2, 2023, by and among Amicus as the borrower, certain subsidiaries of Amicus as guarantors, Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative” and referred to herein as “Blackstone”) and Wilmington Trust, National Association, (the “Agent”) as the agent for certain lenders from time to time party thereto, governing the Company’s $400 million senior secured term loan. Capitalized terms used but not otherwise defined in this Item 1.01 under the heading “Blackstone Agreement” have the respective meanings ascribed to such terms in the Loan Agreement. The Blackstone Agreement was filed as Exhibit 10.1 to Amicus’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 2, 2023.

     

    Pursuant to the terms of the First Amendment, Amicus, Blackstone and the Agent have agreed to amend the Loan Agreement to (i) include reference to the obtainment of the Dimerix License Agreement and (ii) revise the Permitted Acquisition Aggregate Consideration Limit to account for the $30 million up-front fee in connection with the Dimerix License Agreement.

     

    A copy of the First Amendment is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference. The foregoing description of the First Amendment is qualified in its entirety by reference thereto.

     

    Item 7.01 – Regulation FD Disclosure.

     

    On April 30, 2025, the Company issued a press release announcing its entry into the Agreement, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”), or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Act.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits:

     

    Exhibit No.   Description
    10.1   First Amendment to Loan Agreement, dated April 28, 2025 by and among Amicus Therapeutics, Inc., certain subsidiaries of Amicus Therapeutics, Inc. from time to time party thereto as Guarantors, Blackstone Alternative Credit Advisors LP, Blackstone Life Sciences Advisors L.L.C., certain lenders from time to time party thereto and Wilmington Trust, National Association, as Agent for the lenders.
    99.1   Press Released dated April 30, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    Signature Page

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      AMICUS THERAPEUTICS, INC.
       
    Date: May 1, 2025 By: /s/ Ellen S. Rosenberg
      Name: Ellen S. Rosenberg
      Title: Chief Legal Officer and Corporate Secretary

     

     

    Get the next $FOLD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FOLD

    DatePrice TargetRatingAnalyst
    12/13/2024$17.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    9/6/2024$18.00Buy
    Jefferies
    5/30/2024$18.00Overweight
    Wells Fargo
    5/14/2024$13.00Neutral → Buy
    Guggenheim
    12/19/2023$15.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    9/9/2022$14.00Equal-Weight
    Morgan Stanley
    4/13/2022$11.00Neutral
    Goldman
    2/24/2022$16.00 → $14.00Outperform
    SVB Leerink
    More analyst ratings

    $FOLD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

      PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in Muscle and Nerve. In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured. In PROPEL, 77% of patients (n=95) received enzyme replacement therapy (ERT) with alglucosidase alfa before study entry, with a median ERT duration of 7.4 years. In this new

      6/3/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

      PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies Global Healthcare Conference 2025 in New York, NY, on Wednesday, June 4, 2025, at 11:40 a.m. ETGoldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL, on Tuesday, June 10, 2025, at 2:00 p.m. ET A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (NASDAQ:FOLD) is a global, patient

      5/30/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference

      PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Conference in Las Vegas, NV on Wednesday, May 14, 2025, at 8:00 a.m. P.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (NASDAQ:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordi

      5/7/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

      SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 9:00:58 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Amicus Therapeutics Inc.

      SC 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 11:37:23 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

      SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 9:31:54 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Financials

    Live finance-specific insights

    See more
    • Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates

      1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S. Maintaining 2025 Guidance for Galafold, Reflecting Strong Underlying Demand Updating 2025 Pombiliti + Opfolda Guidance with New Patient Starts Accelerating in 2H Adjusting 2025 Total Revenue Growth Guidance to 15-22% at CER Reiterating GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and c

      5/1/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

      PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com

      4/21/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

      2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2024. "We closed 2024 beating expectations with exceptional revenue growth of 33 percent. With our portfolio and global rare disease capabilities, we have a clear path to deliver cont

      2/19/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Leadership Updates

    Live Leadership Updates

    See more
    • Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

      Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. "Th

      8/21/23 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

      PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company's Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus

      6/14/21 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development

      Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company's corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team. Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President

      5/6/21 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Amicus Therapeutics Inc.

      SCHEDULE 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      5/15/25 9:30:38 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Amicus Therapeutics Inc.

      10-Q - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

      5/1/25 4:02:46 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

      5/1/25 7:00:45 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Campbell Bradley L covered exercise/tax liability with 13,375 shares, decreasing direct ownership by 1% to 1,137,282 units (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      3/18/25 5:56:44 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Campbell Bradley L exercised 400 shares at a strike of $9.03 and sold $4,000 worth of shares (400 units at $10.00) (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      2/21/25 7:27:08 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Accounting Officer Prout Samantha was granted 27,416 shares and covered exercise/tax liability with 13,500 shares, increasing direct ownership by 15% to 109,441 units (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      2/13/25 5:22:50 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amicus Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Amicus Therapeutics from Overweight to Equal-Weight and set a new price target of $12.00 from $17.00 previously

      12/13/24 7:53:22 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Amicus Therapeutics with a new price target

      Jefferies initiated coverage of Amicus Therapeutics with a rating of Buy and set a new price target of $18.00

      9/6/24 7:39:36 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Amicus Therapeutics with a new price target

      Wells Fargo initiated coverage of Amicus Therapeutics with a rating of Overweight and set a new price target of $18.00

      5/30/24 7:51:51 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care